Indication
Micropapillary Variant
3 clinical trials
4 products
5 drugs
Clinical trial
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
AN0025Product
TremelimumabClinical trial
A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
AvelumabProduct
PemetrexedClinical trial
Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder CancerStatus: Terminated, Estimated PCD: 2022-08-11
Drug
CisplatinDrug
doxorubicinDrug
GemcitabineDrug
DocetaxelProduct
Vinblastine